7-E-11-13-G-9

N/A

Report date: 2022/07/01 15:29:28

Base Information

Drug Name7-E-11-13-G-9
Drug Alias Name7E11-13G97-E-11-13-G-9
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CD19CD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Genbase Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Genbase Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A